(0.34%) 5 117.35 points
(0.34%) 38 369 points
(0.39%) 15 990 points
(-0.95%) $83.05
(5.36%) $2.03
(0.34%) $2 355.10
(0.52%) $27.68
(4.09%) $959.85
(-0.27%) $0.932
(-0.45%) $10.98
(-0.58%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.39%
@ $15.52
発行日: 15 2月 2024 @ 03:33
リターン: -49.58%
前回のシグナル: 2月 14 - 04:42
前回のシグナル:
リターン: 2.37 %
Live Chart Being Loaded With Signals
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union...
Stats | |
---|---|
本日の出来高 | 811 957 |
平均出来高 | 4.57M |
時価総額 | 1.22B |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $0.190 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.210 |
ATR14 | $0.00700 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | Denner Alexander J | Buy | 1 662 | Class A Common Stock |
2024-03-08 | John Minardo | Buy | 32 752 | Class A Common Stock |
2024-03-08 | John Minardo | Sell | 32 752 | Performance-based Restricted Stock Unit |
2024-03-08 | Emany Sravan Kumar | Buy | 37 120 | Class A Common Stock |
2024-03-08 | Emany Sravan Kumar | Sell | 37 120 | Performance-based Restricted Stock Unit |
INSIDER POWER |
---|
45.56 |
Last 100 transactions |
Buy: 2 835 189 | Sell: 1 035 601 |
ボリューム 相関
Ironwood Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
APOP | -0.924 |
KTOS | -0.921 |
SIBN | -0.912 |
PPD | -0.91 |
BNIX | -0.905 |
ARIZ | -0.903 |
IPAR | -0.902 |
OXAC | -0.9 |
WTMA | -0.896 |
PPYA | -0.895 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Ironwood Pharmaceuticals 相関 - 通貨/商品
Ironwood Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $442.74M |
総利益: | $441.16M (99.64 %) |
EPS: | $-6.45 |
FY | 2023 |
収益: | $442.74M |
総利益: | $441.16M (99.64 %) |
EPS: | $-6.45 |
FY | 2022 |
収益: | $410.60M |
総利益: | $409.18M (99.65 %) |
EPS: | $1.130 |
FY | 2021 |
収益: | $413.75M |
総利益: | $413.75M (100.00 %) |
EPS: | $3.26 |
Financial Reports:
No articles found.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。